Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Elpiscience Raises $105 Million for Cancer Immunotherapy Portfolio

publication date: May 13, 2021

Elpiscience Biopharma, a Shanghai cancer immunotherapy company, closed a $105 million Series C round to start US trials of its innovative portfolio. The company also plans to research novel mechanisms for cancer immunotherapy and support additional partnerships. Elpiscience has built a pipeline of 15 innovative molecules, including three candidates in clinical trials and three in-house developed molecules at the IND-enabling stage. The company says its candidates must have a differentiated biology that shows efficacy in a clinical setting platform. The C round was led by the Greater Bay Area Homeland Development Fund. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital